{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T17:08:26Z","timestamp":1774890506085,"version":"3.50.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.phrs.2008.10.002","type":"journal-article","created":{"date-parts":[[2008,10,18]],"date-time":"2008-10-18T05:00:59Z","timestamp":1224306059000},"page":"81-89","source":"Crossref","is-referenced-by-count":73,"title":["The future (or lack of future) of personalized prescription in psychiatry"],"prefix":"10.1016","volume":"59","author":[{"given":"Jose","family":"de Leon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2008.10.002_bib1","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1001\/jama.286.18.2289","article-title":"The anatomy of the human genome: a neo-vesalian basis for medicine in the 21st century","volume":"286","author":"McKusick","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2008.10.002_bib2","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nature01626","article-title":"A vision for the future of genomics research","volume":"422","author":"Collins","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2008.10.002_bib3","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1136\/bmj.322.7293.1027","article-title":"The challenge of integrating genetic medicine into primary care","volume":"322","author":"Emery","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2008.10.002_bib4","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1001\/jama.286.18.2270","article-title":"Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review","volume":"286","author":"Phillips","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2008.10.002_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1126\/science.277.5324.393","article-title":"Massively parallel genomics","volume":"277","author":"Fodor","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.phrs.2008.10.002_bib6","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrd1496","article-title":"Technology platforms for pharmacogenomic diagnostic assays","volume":"3","author":"Koch","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.phrs.2008.10.002_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/biot.200600213","article-title":"Whole genome genotyping technologies on the BeadArray platform","volume":"2","author":"Steemers","year":"2007","journal-title":"Biotechnol J"},{"key":"10.1016\/j.phrs.2008.10.002_bib8","unstructured":"Golden F, Lemonick MD. The race is over. Time 2000;July3:18\u201323."},{"key":"10.1016\/j.phrs.2008.10.002_bib9","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/35057062","article-title":"Initial sequencing and analysis of the human genome","volume":"409","author":"Lander","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2008.10.002_bib10","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1126\/science.1058040","article-title":"The sequence of the human genome","volume":"291","author":"Venter","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.phrs.2008.10.002_bib11","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1001\/jama.286.18.2296","article-title":"Implications of the human genome for understanding human biology and medicine","volume":"286","author":"Subramanian","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2008.10.002_bib12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.tibs.2007.10.001","article-title":"Quo vadis genoma? A call for pipettes for biochemists","volume":"32","author":"Reichardt","year":"2007","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.phrs.2008.10.002_bib13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.tig.2008.03.002","article-title":"Realizing the full potential of the sequenced human genome (letter)","volume":"24","author":"Reichardt","year":"2008","journal-title":"Trends Genet"},{"key":"10.1016\/j.phrs.2008.10.002_bib14","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nature05329","article-title":"Global variation in copy number in the human genome","volume":"444","author":"Redon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2008.10.002_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2217\/14622416.7.1.25","article-title":"Copy number variants and pharmacogenomics","volume":"7","author":"Ouahchi","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.phrs.2008.10.002_bib16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","article-title":"Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects","volume":"116","author":"Ingelman-Sundberg","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.phrs.2008.10.002_bib17","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/0091270007303768","article-title":"A pharmacogenomics primer","volume":"47","author":"Court","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.phrs.2008.10.002_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/03602530801952864","article-title":"From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions","volume":"40","author":"Nebert","year":"2008","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.phrs.2008.10.002_bib19","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1371\/journal.pbio.0050265","article-title":"Drug-induced epigenetic changes produce drug tolerance","volume":"5","author":"Wang","year":"2007","journal-title":"PLoS Biol"},{"key":"10.1016\/j.phrs.2008.10.002_bib20","first-page":"52","article-title":"Moderne probleme der Humangenetik","volume":"12","author":"Vogel","year":"1959","journal-title":"Ergeb Inn Med Kinderheild"},{"key":"10.1016\/j.phrs.2008.10.002_bib21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.0306-5251.2001.01498.x","article-title":"Pharmacogenetics and pharmacogenomics","volume":"52","author":"Pirmohamed","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.phrs.2008.10.002_bib22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrg1432","article-title":"Pharmacogenetics and drug development: the path to safer and more effective drugs","volume":"5","author":"Roses","year":"2004","journal-title":"Nat Rev"},{"key":"10.1016\/j.phrs.2008.10.002_bib23","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1146\/annurev.pharmtox.48.113006.094611","article-title":"Strategic approach to fit-for-purpose biomarkers in drug development","volume":"48","author":"Wagner","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.phrs.2008.10.002_bib24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1155\/2002\/341708","article-title":"Pharmacogenomic biomarkers","volume":"18","author":"Kirkwood","year":"2002","journal-title":"Dis Markers"},{"key":"10.1016\/j.phrs.2008.10.002_bib25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1146\/annurev.pharmtox.41.1.347","article-title":"Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies","volume":"41","author":"Lesko","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.phrs.2008.10.002_bib26","unstructured":"FDA. Guidance for Industry: Pharmacogenomic data submission. FDA 2005. http:\/\/www.fda.gov\/cder\/guidance\/6400fnl.pdf (Viewed in April 2008)."},{"key":"10.1016\/j.phrs.2008.10.002_bib27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1517\/14622416.5.5.503","article-title":"Pharmacogenomics data: FDA voluntary and required submission guidance","volume":"5","author":"Salerno","year":"2005","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.phrs.2008.10.002_bib28","doi-asserted-by":"crossref","first-page":"15533","DOI":"10.1073\/pnas.0507666102","article-title":"Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia","volume":"102","author":"Glatt","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2008.10.002_bib29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.schres.2007.05.020","article-title":"Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy","volume":"96","author":"de Leon","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.phrs.2008.10.002_bib30","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.clpt.6100204","article-title":"Personalized medicine: elusive dream or imminent reality?","volume":"81","author":"Lesko","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2008.10.002_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17410541.1.1.1","article-title":"Quo vadis personalized medicine","volume":"1","author":"Rua\u00f1o","year":"2004","journal-title":"Personalized Med"},{"key":"10.1016\/j.phrs.2008.10.002_bib32","unstructured":"Science. New research horizons. Science 1997; 278:2039."},{"key":"10.1016\/j.phrs.2008.10.002_bib33","unstructured":"Lertola J. Deciphering the code and what might come from it. Time 1999;November 8:68\u20139."},{"key":"10.1016\/j.phrs.2008.10.002_bib34","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jama.285.5.540","article-title":"Implications of the human genome project for medical science","volume":"285","author":"Collins","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2008.10.002_bib35","unstructured":"Cappell K, Arndt M, Carey J. Drugs get smart. Business Week 2005;September 5:76\u201385."},{"key":"10.1016\/j.phrs.2008.10.002_bib36","first-page":"243","article-title":"Trastuzumab: targeted therapy for the management of HER-2\/neu-overexpressing metastatic breast cancer","volume":"12","author":"Emens","year":"2005","journal-title":"Am J Ther"},{"key":"10.1016\/j.phrs.2008.10.002_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00129785-200404010-00001","article-title":"Clinical utility of thiopurine S-methyltransferase genotyping","volume":"4","author":"Corominas","year":"2004","journal-title":"Am J Pharmacogenom"},{"key":"10.1016\/j.phrs.2008.10.002_bib38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/JCP.0b013e318058244d","article-title":"The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 and CYP2C19","volume":"27","author":"de Leon","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.phrs.2008.10.002_bib39","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/jmp\/jhn004","article-title":"The prototype resemblance theory of disease","volume":"33","author":"Sadegh-Zadeh","year":"2008","journal-title":"J Med Phil"},{"key":"10.1016\/j.phrs.2008.10.002_bib40","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","article-title":"Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects","volume":"116","author":"Ingelman-Sundberg","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.phrs.2008.10.002_bib41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1176\/appi.psy.47.1.75","article-title":"Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19","volume":"47","author":"de Leon","year":"2006","journal-title":"Psychosomatics"},{"key":"10.1016\/j.phrs.2008.10.002_bib42","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1017\/S1092852900014887","article-title":"A poor metabolizer for both Cytochrome P450 2D6 and 2C19 (CYP2D6 and CYP2C19): a case report on antidepressant treatment","volume":"11","author":"Johnson","year":"2006","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.phrs.2008.10.002_bib43","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1176\/appi.psy.46.3.262","article-title":"The dosing of atypical antipsychotics","volume":"46","author":"de Leon","year":"2005","journal-title":"Psychosomatics"},{"key":"10.1016\/j.phrs.2008.10.002_bib44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1017\/S1461145703003249","article-title":"Glucuronidation enzymes, genes and psychiatry","volume":"6","author":"de Leon","year":"2003","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.phrs.2008.10.002_bib45","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1211\/0022357043969","article-title":"Identification of p-glycoprotein substrates and inhibitors among psychoactive compounds\u2014implications for pharmacokinetics of selected substrates","volume":"56","author":"El Ela","year":"2004","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.phrs.2008.10.002_bib46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0024-3205(02)01680-6","article-title":"In vitro P-glycoprotein affinity for atypical and conventional antipsychotics","volume":"71","author":"Boulton","year":"2002","journal-title":"Life Sci"},{"key":"10.1016\/j.phrs.2008.10.002_bib47","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1124\/mol.107.041210","article-title":"Seizure-induced up-regulation of P-glycoprotein at the blood\u2013brain barrier through glutamate and cyclooxygenase-2 signaling","volume":"73","author":"Bauer","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2008.10.002_bib48","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S1461145704004390","article-title":"The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by p-glycoprotein","volume":"7","author":"Wang","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.phrs.2008.10.002_bib49","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1176\/appi.psy.49.3.258","article-title":"A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics. Part I","volume":"49","author":"de Leon","year":"2008","journal-title":"Psychosomatics"},{"key":"10.1016\/j.phrs.2008.10.002_bib50","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1176\/appi.psy.49.4.347","article-title":"A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics. Part II","volume":"49","author":"de Leon","year":"2008","journal-title":"Psychosomatics"},{"key":"10.1016\/j.phrs.2008.10.002_bib51","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2165\/00002018-200528090-00004","article-title":"The role of p-glycoprotein and organic anion-transporting polypeptides in drug interactions","volume":"28","author":"Dubuske","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.phrs.2008.10.002_bib52","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ejps.2005.11.002","article-title":"The role of transporters in drug interactions","volume":"27","author":"Endres","year":"2006","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.phrs.2008.10.002_bib53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v66n0103","article-title":"The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation","volume":"66","author":"de Leon","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.phrs.2008.10.002_bib54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2007-973836","article-title":"A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels","volume":"40","author":"de Leon","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.phrs.2008.10.002_bib55","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2007-1004591","article-title":"Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables","volume":"41","author":"Diaz","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.phrs.2008.10.002_bib56","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.pnpbp.2008.04.018","article-title":"Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model","volume":"32","author":"Botts","year":"2008","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.phrs.2008.10.002_bib57","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.jcp.0000169418.31275.a7","article-title":"Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service","volume":"25","author":"Reimers","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.phrs.2008.10.002_bib58","unstructured":"Preskorn S. Outpatient management of depression: a guide for the primary-care practitioner. Professional Communications, Inc., Caddo, OK, 1999."},{"key":"10.1016\/j.phrs.2008.10.002_bib59","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.pbb.2008.03.015","article-title":"The value of genetic and pharmacological approaches to understanding the complexities of GABA(A) receptor subtype functions: the anxiolytic effects of benzodiazepines","volume":"90","author":"Reynolds","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"issue":"Suppl. 4","key":"10.1016\/j.phrs.2008.10.002_bib60","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1016\/S0924-977X(08)70223-2","article-title":"Pharmacogenetics of mood stabilizers in bipolar disorder","volume":"18","author":"de Leon","year":"2008","journal-title":"Eur Neuropychopharmacol"},{"key":"10.1016\/j.phrs.2008.10.002_bib61","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.mp.4002009","article-title":"Pharmacogenetics and pharmacogenomics of schizophrenia: a review of the last decade of research","volume":"12","author":"Arranz","year":"2007","journal-title":"Mol Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2008.10.002_bib62","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00406-007-1004-z","article-title":"Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics","volume":"258","author":"Maier","year":"2008","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.phrs.2008.10.002_bib63","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.4088\/JCP.v65n0817","article-title":"Variables associated with high olanzapine dosing in a state hospital","volume":"65","author":"Botts","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.phrs.2008.10.002_bib64","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0163-7258(99)00048-0","article-title":"Pharmacokinetics of selective serotonin reuptake inhibitors","volume":"85","author":"Hiemke","year":"2000","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.phrs.2008.10.002_bib65","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1126\/science.321.5890.769b","article-title":"The potential of genotyping (letter)","volume":"321","author":"de Leon","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.phrs.2008.10.002_bib66","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/bmj.316.7140.1295","article-title":"Adverse drug reactions","volume":"316","author":"Pirmohamed","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2008.10.002_bib67","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.pharmtox.47.120505.105150","article-title":"Idiosyncratic drug reactions: current understanding","volume":"47","author":"Uetrecht","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.phrs.2008.10.002_bib68","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens\u2013Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2008.10.002_bib69","unstructured":"FDA. Information for Healthcare Professionals: Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics). FDA 2007. http:\/\/www.fda.gov\/cder\/drug\/InfoSheets\/HCP\/carbamazepineHCP.htm."},{"key":"10.1016\/j.phrs.2008.10.002_bib70","unstructured":"Pfizer. GeodonR (ziprasidone HCl), GeodonR (ziprasidone mesylate) for injection for IM use only prescribing information. New York: Roering Division of Pfizer, Inc., March 2007."},{"key":"10.1016\/j.phrs.2008.10.002_bib71","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.phrs.2008.10.002_bib72","first-page":"23","article-title":"A call for the creation of personalized medicine databases","volume":"5","author":"Gurwitz","year":"2006","journal-title":"Nature Rev"},{"key":"10.1016\/j.phrs.2008.10.002_bib73","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2217\/14622416.8.2.177","article-title":"Mapping translational research in personalized therapeutics: from molecular markers to health policy","volume":"8","author":"Ozdemir","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.phrs.2008.10.002_bib74","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/01.jcp.0000177546.34799.af","article-title":"Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6 CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness","volume":"25","author":"de Leon","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.phrs.2008.10.002_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhealeco.2004.08.001","article-title":"Do new prescription drugs pay for themselves? The case of second-generation antipsychotics","volume":"24","author":"Duggan","year":"2005","journal-title":"J Health Econ"},{"key":"10.1016\/j.phrs.2008.10.002_bib76","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1176\/ps.2008.59.5.515","article-title":"Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making","volume":"59","author":"Rosenheck","year":"2008","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.phrs.2008.10.002_bib77","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1176\/ajp.2007.164.3.415","article-title":"Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study","volume":"164","author":"Stroup","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"September 15","key":"10.1016\/j.phrs.2008.10.002_bib78","article-title":"Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study","author":"Sikich","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.phrs.2008.10.002_bib79","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1517\/14656566.7.2.119","article-title":"Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines","volume":"7","author":"Ozdemir","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.phrs.2008.10.002_bib80","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/sj.mp.4001944","article-title":"Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients","volume":"12","author":"Rua\u00f1o","year":"2007","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.phrs.2008.10.002_bib81","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004714-200102000-00016","article-title":"The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine","volume":"21","author":"Wong","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.phrs.2008.10.002_bib82","doi-asserted-by":"crossref","unstructured":"de Leon J, Arranz MJ, Rua\u00f1o G. Products for pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med 2008; 28 4.","DOI":"10.1016\/j.cll.2008.05.003"},{"issue":"September 17","key":"10.1016\/j.phrs.2008.10.002_bib83","article-title":"Pharmacogenomics: the promise of personalized medicine for CNS disorders","author":"de Leon","year":"2008","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.phrs.2008.10.002_bib84","first-page":"22","article-title":"Discovery of genetic markers associated with clozapine induced agranulocytosis","volume":"138b","author":"Malhotra","year":"2005","journal-title":"Am J Med Gen Part B Neuropsychatr Gen"},{"key":"10.1016\/j.phrs.2008.10.002_bib85","unstructured":"LGC. Clozapine response test: Pharmacogenetics in psychiatry. http:\/\/newsite.lgc.co.uk\/our_science\/pharmacogenetics.aspx. (Viewed in October 2008)."},{"key":"10.1016\/j.phrs.2008.10.002_bib86","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1586\/14737159.6.3.277","article-title":"The AmpliChip CYP450 Test: personalized medicine has arrived in psychiatry","volume":"6","author":"de Leon","year":"2006","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.phrs.2008.10.002_bib87","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.mp.4001494","article-title":"Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response","volume":"9","author":"Kirchheiner","year":"2004","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.phrs.2008.10.002_bib88","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF03256453","article-title":"The AmpliChip CYP450 Genotyping Test: integrating a new clinical tool","volume":"10","author":"de Leon","year":"2006","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.phrs.2008.10.002_bib89","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1373\/clinchem.2006.081539","article-title":"Validation of a CYP2D6 genotyping panel on the NanoChip Molecular BiologyWorkstation","volume":"53","author":"Lee","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.phrs.2008.10.002_bib90","unstructured":"Nanosphere, Inc. Nanosphere announces FDA clearance of second molecular diagnostics assay. October 16, 2007. http:\/\/ir.nanosphere.us\/phoenix.zhtml?c=214748&p=irol-newsArticle&ID=1075929&highlight=. (Viewed in October 2008)."},{"key":"10.1016\/j.phrs.2008.10.002_bib91","first-page":"15","article-title":"Pyrosequencing applications","volume":"373","author":"Marsh","year":"2007","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.phrs.2008.10.002_bib92","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","article-title":"The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry","volume":"37","author":"Baumann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.phrs.2008.10.002_bib93","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1002\/jps.20892","article-title":"CYP2D6 polymorphisms and the impact on tamoxifen therapy","volume":"96","author":"Beverage","year":"2007","journal-title":"J Pharm Sci"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661808001989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661808001989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T15:39:00Z","timestamp":1557848340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661808001989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S1043661808001989"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2008.10.002","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}